Stockscreener 앱 받기
10.79
0.28%
0.03
전일 마감가:
$10.76
열려 있는:
$10.75
하루 거래량:
3.71M
Relative Volume:
0.58
시가총액:
$7.70B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
1.9097
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
+1.41%
1개월 성능:
+7.68%
6개월 성능:
-3.66%
1년 성능:
-5.43%
1일 변동 폭
$10.65
$10.87
1주일 범위
$10.58
$11.06
52주 변동 폭
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.79 | 7.59B | 125.68M | 4.81B | -781.21M | 5.65 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Don't Ignore The Insider Selling In Roivant Sciences - simplywall.st
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Roivant Sciences at BofA Securities: Strategic Shifts and Litigation Focus By Investing.com - Investing.com India
Transcript : Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Roivant Sciences at BofA Securities: Strategic Shifts and Litigation Focus - Investing.com Australia
How To Trade (ROIV) - news.stocktradersdaily.com
(ROIV) On The My Stocks Page - news.stocktradersdaily.com
Roivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside Potential - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update - ADVFN
Roivant Sciences: Primed For Growth With A De-Risked Pipeline (NASDAQ:ROIV) - Seeking Alpha
Roivant sciences president Eric Venker sells $1.02 million in stock By Investing.com - Investing.com India
Roivant sciences president Eric Venker sells $1.02 million in stock - Investing.com
Roivant Sciences stock holds $18 target, management shuffle - Investing.com Australia
Roivant Sciences stock holds $18 target, management shuffle By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains overweight on Roivant Sciences stock - Investing.com Australia
Immunovant makes leadership changes - MSN
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Cantor Fitzgerald maintains overweight on Roivant Sciences stock By Investing.com - Investing.com South Africa
Immunovant, Inc. Announces the Expanded Development of Imvt-1402 into Two New Indications, Sjd and Cle - marketscreener.com
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - marketscreener.com
When (ROIV) Moves Investors should Listen - news.stocktradersdaily.com
Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In - Insider Monkey
ROIV Factor-Based Stock Analysis - Nasdaq
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
Knott David M Jr Decreases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
KLP Kapitalforvaltning AS Invests $918,000 in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIV stock touches 52-week low at $9.96 amid market fluctuations By Investing.com - Investing.com South Africa
ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com Australia
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
Roivant Sciences president Eric Venker sells shares worth $8.19 million By Investing.com - Investing.com UK
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
(ROIV) Trading Advice - news.stocktradersdaily.com
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Critical Clinical Data Coming: Roivant's Dual Breakthrough Results in MG and CIDP Studies - Stock Titan
(ROIV) Trading Signals - Stock Traders Daily
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ramaswamy Vivek | 10% Owner |
May 06 '25 |
Sale |
11.47 |
273,959 |
3,142,310 |
39,799,611 |
1.54%
7.58%
자본화:
|
볼륨(24시간):